You might  be offered lutetium-177-DOTA-octreotate (commonly ‘Lu-TATE’ or lutetium octreotate) if you have tumours that come from your endocrine or system that is nervous. These are commonly known as neuroendocrine tumours (NETs).

Lutetium octreotate therapy is certainly one of  team of innovative treatments known as Peptide Receptor Radionuclide Therapy (PRRT). It combines octreotate, a manufactured form of the naturally produced hormone somatostatin, and lutetium-177, an element that releases radiation as  a tumour.

Lutetium octreotate treatment aims to stop NETs from growing. Additionally reduce their size. It does this by damaging cells in  the tumour which stops them multiplying. It may suggest the NETs become smaller for very long periods of time, which may relieve your symptoms but it is not just a cure for your cancer. So how exactly  does lutetium octreotate therapy work?

Cells have many different types of receptors on their area. These allow cells to send signals to  other cells. The signals coordinate your system functions. They are helped by them react to changes  in their environment.

The hormones somatostatin is produced by your endocrine system. It has numerous functions. Many cells in your body have receptors for somatostatin. NETs usually have number that is large of receptors on their surface.

Artificial octreotate is similar to your normal somatostatin. It locks onto the somatostatin receptors. It attaches to NET cells and to some normal organs when it’s injected into your body.

Lutetium-177 octreotate treatment involves connecting an isotope, , to this man-made octreotate.

The part that is lutetium-177 of compound is radioactive. The octreotate molecule transports the lutetium-177 direct to the tumour  site and attaches to NET cells. It damages them in a targeted way, which means that your whole body is not exposed to radiation.